Current stock page

Financial Data

UTHR Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

UTHRUnited Therapeutics Corporation

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$591.17−$2.14 (−0.36%)

Latest quote

  • Momentum
    68
  • Value
    78
  • Quality
    81
  • Risk resilience
    83
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$832.5M$783.3M$781.5M$790.2M$799.5M$798.6M$794.4M$735.9M
Gross Profit$733.4M$683.8M$648.1M$686.8M$698.6M$711M$701.9M$660M
Operating Income$307.8M$330.8M$325.8M$357.5M$389.3M$364.5M$382.8M$357.7M
Net Income$258.6M$333M$274.9M$364.3M$338.7M$309.5M$322.2M$301.3M
EPS$6.06$7.82$6.32$8.36$7.73$6.86$7.18$6.74
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow$306.5M$313.6M$463.3M$346.2M$562.1M$191.7M$461.2M$341.2M
Capital Expenditure-$180.7M-$108M-$100.8M-$172.9M-$210.5M-$62.2M-$74.9M-$86.7M
Free Cash Flow$125.8M$205.6M$362.5M$173.3M$351.6M$129.5M$386.3M$254.5M
Net Cash Provided By Operating Activities$306.5M$313.6M$463.3M$346.2M$562.1M$191.7M$461.2M$341.2M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$7.03B$7.22B$6.71B$7.88B$7.35B$7.91B$7.74B$7.36B
Total Debt$0$0$0$37.6M$0$0$200M$300M
Cash And Cash Equivalents$1.19B$1.8B$1.28B$1.56B$1.34B$1.59B$1.9B$1.7B
Total Liabilities$758.1M$819.8M$813.1M$783.8M$760.9M$734.4M$936.7M$920M
Total Stockholders Equity$6.28B$6.4B$5.9B$7.1B$6.59B$7.17B$6.81B$6.44B
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio20.8218.1321.8819.216.9410.9612.1712.99
P/B ratio4.083.714.773.613.271.92.162.41
P/S ratio7.92———————
Debt To Equity0000.01000.030.05
Free Cash Flow Yield3.38%4.60%3.61%4.06%5.21%7.86%7.66%6.96%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio20.8218.1321.8819.216.9410.9612.1712.99
P/B ratio4.083.714.773.613.271.92.162.41
P/S ratio7.92———————
Return On Equity19.61%20.48%21.82%18.81%19.30%17.31%17.79%18.55%
Debt To Equity0000.01000.030.05

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe20.7x
Pb4.02x
Revenue Growth Yoy4.13%
EPS Growth Yoy-21.60%
Gross Margin86.34%
Operating Margin41.47%
ROE19.18%
ROIC16.83%
Debt To Equity0
FCF Yield3.44%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$591.17
Volume463,509
RSI (14)58.01
MACD12.7
MACD signal14.67
MACD histogram-1.97
ADX (14)20.93
SMA (50)$542.60
SMA (200)$537.46
ATR (14)$18.18
Historical volatility (annualized)34.76%
Volume (20-day average)527,296

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score83/100
Beta0.42
Annual volatility35.02%
Max Drawdown-20.87%
Sharpe Ratio0.76
VaR (95%, 1-day)-2.44%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

UTHR Financial Data FAQ

What is United Therapeutics Corporation's revenue?

United Therapeutics Corporation's revenue is one of the core financial data points for UTHR. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is United Therapeutics Corporation's revenue growing?

Revenue growth shows whether United Therapeutics Corporation is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is UTHR's EPS?

UTHR's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is United Therapeutics Corporation's net income?

United Therapeutics Corporation's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does United Therapeutics Corporation generate?

Free cash flow shows how much cash United Therapeutics Corporation generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does United Therapeutics Corporation have?

Cash and debt help frame UTHR's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.